Concetta Valentina Tropeano

Concetta Valentina Tropeano

Auto-generated profile, based on publicly available information

Concetta Valentina Tropeano

Programma di Neurogenetica, IRCCS Istituto delle Scienze Neurologiche di Bologna , Bologna 40139

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2019 in Biochimica et Biophysica Acta (BBA) - Bioenergetics
Verified
Journal Article
Closed access
CTConcetta V. Tropeano
Concetta V. Tropeano
SASerena J. Aleo
Serena J. Aleo
Claudia ZannaClaudia Zanna
Claudia Zanna
MRMarina Roberti
Marina Roberti
LSLetizia Scandiffio
Letizia Scandiffio
AGAnna Ghelli
Anna Ghelli

4 March 2025 in Brain Communications
Verified
Journal Article
Open access
MMMonica Moresco
Monica Moresco
CTConcetta Valentina Tropeano
Concetta Valentina Tropeano
MRMartina Romagnoli
Martina Romagnoli
GNGiulia Neccia
Giulia Neccia
ARAlessandro Rapone
Alessandro Rapone
GPGiuseppe Plazzi
Giuseppe Plazzi
Narcolepsy type 1 (NT1) is a rare neurological disorder characterized by excessive daytime sleepiness and cataplexy, thought to result from an autoimmune process targeting the hypothalamic hypocretin-producing neurons. Aiming to add clues to the latter hypothesis, we investigated circulating cell-free mitochondrial DNA (ccf-mtDNA) levels in cerebrospinal fluid (CSF), a possible biomarker for neurodegeneration, neuroinflammation or immune activation, from 46 NT1 patients with low CSF hypocretin-1, compared with 32 controls. We found significantly increased ccf-mtDNA levels in NT1 patients compared with controls, which negatively correlated with CSF hypocretin-1 concentrations. Additionally, higher ccf-mtDNA levels were observed in patients with elevated number of sleep onset rapid eye movement periods. These observations imply that increased levels of ccf-mtDNA associate with reduced CSF hypocretin-1 concentrations leading to greater alteration in sleep architecture. Furthermore, cytokine profiling in CSF revealed significant changes in interleukins 6 and 18 in NT1 patients, suggesting an active neuroinflammatory process possibly linked to ccf-mtDNA release, thus pointing to a specific inflammatory signature in NT1. These findings hint a potential mitochondrial dysfunction and neuroinflammation in NT1. Further studies are needed to elucidate the underlying mechanisms and how this may reflect on therapy.